Affordable Access

deepdyve-link
Publisher Website

Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling.

Authors
  • Bernardo, Bianca C1, 2
  • Weeks, Kate L1
  • Pongsukwechkul, Thawin3, 4
  • Gao, Xiaoming3
  • Kiriazis, Helen3
  • Cemerlang, Nelly3
  • Boey, Esther J H3
  • Tham, Yow Keat3, 5
  • Johnson, Chad J6
  • Qian, Hongwei3
  • Du, Xiao-Jun3, 5
  • Gregorevic, Paul3, 7, 8, 9
  • McMullen, Julie R1, 5, 10
  • 1 Baker Heart and Diabetes Institute, Melbourne 3004, Australia [email protected] [email protected] [email protected] , (Australia)
  • 2 Department of Paediatrics, University of Melbourne, Parkville 3052, Australia. , (Australia)
  • 3 Baker Heart and Diabetes Institute, Melbourne 3004, Australia. , (Australia)
  • 4 Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville 3052, Australia. , (Australia)
  • 5 Department of Medicine, Monash University, Clayton 3800, Australia. , (Australia)
  • 6 Monash Micro Imaging, Burnet Institute, Melbourne 3004, Australia. , (Australia)
  • 7 Department of Physiology, University of Melbourne, Parkville 3052, Australia. , (Australia)
  • 8 Department of Biochemistry and Molecular Biology, Monash University, Clayton 3800, Australia. , (Australia)
  • 9 Department of Neurology, The University of Washington School of Medicine, Seattle, WA 98195, U.S.A.
  • 10 Department of Physiology, Monash University, Clayton 3800, Australia. , (Australia)
Type
Published Article
Journal
Clinical Science
Publisher
Portland Press
Publication Date
Feb 14, 2018
Volume
132
Issue
3
Pages
381–397
Identifiers
DOI: 10.1042/CS20171269
PMID: 29358507
Source
Medline
Keywords
License
Unknown

Abstract

We previously showed that medium chain acyl-coenzyme A dehydrogenase (MCAD, key regulator of fatty acid oxidation) is positively modulated in the heart by the cardioprotective kinase, phosphoinositide 3-kinase (PI3K(p110α)). Disturbances in cardiac metabolism are a feature of heart failure (HF) patients and targeting metabolic defects is considered a potential therapeutic approach. The specific role of MCAD in the adult heart is unknown. To examine the role of MCAD in the heart and to assess the therapeutic potential of increasing MCAD in the failing heart, we developed a gene therapy tool using recombinant adeno-associated viral vectors (rAAV) encoding MCAD. We hypothesised that increasing MCAD expression may recapitulate the cardioprotective properties of PI3K(p110α). rAAV6:MCAD or rAAV6:control was delivered to healthy adult mice and to mice with pre-existing pathological hypertrophy and cardiac dysfunction due to transverse aortic constriction (TAC). In healthy mice, rAAV6:MCAD induced physiological hypertrophy (increase in heart size, normal systolic function and increased capillary density). In response to TAC (~15 weeks), heart weight/tibia length increased by ~60% in control mice and ~45% in rAAV6:MCAD mice compared with sham. This was associated with an increase in cardiomyocyte cross-sectional area in both TAC groups which was similar. However, hypertrophy in TAC rAAV6:MCAD mice was associated with less fibrosis, a trend for increased capillary density and a more favourable molecular profile compared with TAC rAAV6:control mice. In summary, MCAD induced physiological cardiac hypertrophy in healthy adult mice and attenuated features of pathological remodelling in a cardiac disease model.

Report this publication

Statistics

Seen <100 times